The company said the discontinuation was due to several reasons,” Reuters news service reported, “including limited interest ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to grant Novavax full approval – without restrictions -- by its April 1 target ...

May 15 (Reuters) - The U.S. Food and Drug Administration has approved ... Axsome Therapeutics' <AXSM.O> recently approved Symbravo and Pfizer's (PFE.N), opens new tab Nurtec ODT.

Pfizer’s anti-TFPI antibody marstacimab has been approved by the FDA to treat haemophilia ... in patients aged 12 and older and is the first drug in the anti-TFPI class to be approved in ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

One possible explanation for the gap is the availability of highly efficacious CAR-T therapies in the U.S. and Europe serving as later-line therapies to improve survival outcomes. The FDA has also ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Pfizer’s Mylotarg is back ... after the FDA reapproved it in the aggressive blood cancer, acute myeloid leukaemia. The world’s first approved antibody-drug conjugate, where a targeted antibody ...

(Reuters) -The U.S. Food and Drug Administration has approved ... include Axsome Therapeutics' recently approved Symbravo and Pfizer's Nurtec ODT. Pfizer also sells a nasal spray, Zavzpret ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

Here are some of the most anticipated drugs ... an FDA decision is expected in early 2025. Mirdametinib for neurofibromatosis Type 1: Pfizer and SpringWorks Therapeutics are seeking approval ...